{{Rsnum
|rsid=1643649
|Gene=DHFR
|Chromosome=5
|position=80643630
|Orientation=plus
|GMAF=0.2029
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=DHFR
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 6.2 | 36.9 | 56.9
| HCB | 0.0 | 8.9 | 91.1
| JPT | 0.0 | 2.2 | 97.8
| YRI | 4.8 | 46.8 | 48.4
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 8.9 | 91.1
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1643649
|Name_s=DHFR:rs1643649 in intron 3; rs1643649T>C
|Gene_s=DHFR
|Feature=
|Evidence=PubMed ID:19683694
|Annotation=Risk or phenotype-associated allele: T Phenotype: The T variant of rs1643649 was associated with Spina Bifida in a transmission disequilibrium test. Study size: 610 families (329 trios, 281 duos) Study population/ethnicity: Patients affected with Spina Bifida and their parents; Houston, TX; Los Angeles, CA; Toronto, ON, Canada Significance metric(s): p = 0.0411 Type of association: CO
|Drugs=
|Drug Classes=
|Diseases=Neural Tube Defects; Spina Bifida Cystica
|Curation Level=Curated
|PharmGKB Accession ID=PA165223219
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1643649
|overall_frequency_n=29
|overall_frequency_d=128
|overall_frequency=0.226562
|n_genomes=21
|n_genomes_annotated=0
|n_haplomes=26
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}